{"title":"成纤维细胞生长因子23作为治疗靶点","authors":"Fan Li, Zhousheng Xiao","doi":"10.17140/npoj-4-118","DOIUrl":null,"url":null,"abstract":"This fibroblast growth factor-23 (FGF-23) has been found as a circulating hormone and pathogenic factor in many disease conditions. This review focuses on recent advances in FGF-23 as a therapeutic target, including fibroblast growth factor receptors (FGFR) tyrosine kinase inhibitor, FGF-23 antibody, FGF-23 C-terminal peptide, CYP24A1 inhibitor, and FGF-23 antagonist. We also update the advantages and disadvantages of targeting upstream and downstream molecules in FGF-23 signaling pathways.","PeriodicalId":38952,"journal":{"name":"Open Urology and Nephrology Journal","volume":"6 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2018-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Fibroblast Growth Factor 23 as a Therapeutic Target\",\"authors\":\"Fan Li, Zhousheng Xiao\",\"doi\":\"10.17140/npoj-4-118\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"This fibroblast growth factor-23 (FGF-23) has been found as a circulating hormone and pathogenic factor in many disease conditions. This review focuses on recent advances in FGF-23 as a therapeutic target, including fibroblast growth factor receptors (FGFR) tyrosine kinase inhibitor, FGF-23 antibody, FGF-23 C-terminal peptide, CYP24A1 inhibitor, and FGF-23 antagonist. We also update the advantages and disadvantages of targeting upstream and downstream molecules in FGF-23 signaling pathways.\",\"PeriodicalId\":38952,\"journal\":{\"name\":\"Open Urology and Nephrology Journal\",\"volume\":\"6 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-12-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Open Urology and Nephrology Journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.17140/npoj-4-118\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Open Urology and Nephrology Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17140/npoj-4-118","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
Fibroblast Growth Factor 23 as a Therapeutic Target
This fibroblast growth factor-23 (FGF-23) has been found as a circulating hormone and pathogenic factor in many disease conditions. This review focuses on recent advances in FGF-23 as a therapeutic target, including fibroblast growth factor receptors (FGFR) tyrosine kinase inhibitor, FGF-23 antibody, FGF-23 C-terminal peptide, CYP24A1 inhibitor, and FGF-23 antagonist. We also update the advantages and disadvantages of targeting upstream and downstream molecules in FGF-23 signaling pathways.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
